Guidant's drug-eluting stent programme gets boost
This article was originally published in Clinica
Executive Summary
Guidant is to license the immune suppressing drug everolimus from Novartis for use in drug-eluting stents for the treatment of coronary and peripheral vascular diseases. The deal comes less than a month after Guidant halted trials of its actinomycin-D coated stent programme (see Clinica No 999, 25).